Summary

U.S. X-ray Irradiation Market Trends

The U.S. X-ray irradiation market size was valued at USD 365.98 million in 2024 and is expected to grow at a CAGR of 11.95% from 2025 to 2033. The growth is attributed to a combination of regulatory initiatives, healthcare advancements, and national security priorities. A key driver is the Cesium Irradiator Replacement Project (CIRP) led by the U.S. Department of Energy, which provides funding and support for replacing cesium-137-based devices with non-radioactive X-ray systems in hospitals, research labs, and blood centers. The growing prevalence of cancer, transplant procedures, and immunocompromised patient populations has heightened the need for safe, efficient blood irradiation technologies. Moreover, the U.S. hosts one of the world’s largest biomedical research networks, where X-ray irradiators are increasingly used for radiobiology, oncology, and preclinical applications, strengthened by federal research grants and institutional investments. With strict regulatory oversight from agencies like the FDA and NRC, the U.S. remains at the forefront of adopting innovative, secure, and compliant X-ray irradiation solutions.

The industry is further propelled by expansions, such as in May 2025, Sterigenics’ announcement of new X-ray sterilization capabilities in the Southeast United States, reflecting rising demand for non-radioactive, scalable sterilization solutions. This move underscores the growing need for regional access to safe and efficient medical device sterilization, particularly as healthcare providers and manufacturers seek alternatives to gamma and ethylene oxide methods amid increasing regulatory scrutiny. Such investments support faster turnaround times and reduced logistics costs and align with national efforts to modernize sterilization infrastructure and phase out radioactive materials, supporting the U.S. market’s leadership in advanced X-ray irradiation technologies.

The growing shift toward outsourcing sterilization services significantly drives the industry, as medical device manufacturers, pharmaceutical firms, and healthcare providers seek more cost-effective and compliant solutions. By partnering with specialized third-party sterilization providers, these organizations can reduce capital investments in in-house infrastructure and benefit from established service providers' expertise, scalability, and regulatory readiness. For instance, IBA's agreement with Steri-Tek in June 2024 to install a fully integrated Be Wide X-ray solution underscores how service providers are expanding capacity to meet growing client needs. These developments illustrate how outsourcing trends fuel investment and innovation in the market.

The rising prevalence of cancer in the U.S. is a major driver of the X-ray irradiation market, as it increases the demand for safe and reliable blood transfusion practices and advanced research tools. Cancer patients undergoing chemotherapy, radiation therapy, or bone marrow transplants are highly immunocompromised and require irradiated blood components to prevent life-threatening conditions such as Transfusion-associated Graft versus Host Disease (TA-GvHD). This has led to the adoption of X-ray blood irradiators in hospitals and transfusion centers as a safer alternative to cesium-based devices. Additionally, the surge in oncology research across U.S. academic institutions and biopharma companies fuels demand for precise, benchtop X-ray systems used in radiobiology and cancer modeling. According to the American Cancer Society, with over 2 million new cancer cases projected in 2024, the need for safe transfusion protocols and cancer-focused research infrastructure continues to support strong growth in the market.

U.S. X-ray Irradiation Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. X-ray irradiation market report on the basis of application and size:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
o Medical Devices
o Pharmaceuticals
o Biotech & Laboratory Supplies
o Others
• Size Outlook (Revenue, USD Million, 2021 - 2033)
o Small-scale
o Mid-scale
o Large-scale

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Research Methodology
1.3. Information Procurement
1.4. Purchased database.
1.5. GVR’s internal database
1.6. Secondary sources
1.7. Third Party Perspective
1.8. Primary research
1.9. Details of primary research
1.10. Information or Data Analysis
1.11. Data analysis models
1.12. Market Formulation & Validation
1.13. Model Details
1.14. Commodity flow analysis (Model 1)
1.14.1. Approach 1: Commodity flow approach
1.15. Volume price analysis (Model 2)
1.15.1. Approach 2: Volume price analysis
1.16. List of Secondary Sources
1.17. List of Primary Sources
1.18. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. X-ray Irradiation Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Shift away from radioisotopes
3.2.1.2. Rising healthcare demands
3.2.1.3. Technological advancements
3.2.2. Market Restraint Analysis
3.2.2.1. High initial investment
3.2.2.2. Limited awareness in developing regions
3.2.3. Market Opportunities Analysis
3.2.3.1. Growing biotech and research applications
3.2.4. Market Challenges Analysis
3.2.4.1. Competition from E-beam and gamma irradiation
3.3. U.S. X-ray Irradiation Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & Legal Landscape
3.3.2.2. Economic and Social Landscape
3.3.2.3. Technological landscape
Chapter 4. U.S. X-ray Irradiation Market: Application Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. X-ray Irradiation Market: Application Movement Analysis & Market Share, 2024 & 2033
4.3. Medical Devices
4.3.1. Medical Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Pharmaceuticals
4.4.1. Pharmaceuticals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Biotech & Laboratory Supplies
4.5.1. Biotech & Laboratory Supplies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Others
4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. X-ray Irradiation Market: Size Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. X-ray Irradiation Market: Size Movement Analysis & Market Share, 2024 & 2033
5.3. Small-scale
5.3.1. Small-scale Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Mid-scale
5.4.1. Mid-scale Market Estimates and Forecasts 2021 to 2033 (USD Million)
5.5. Large-scale
5.5.1. Large-scale Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
6.2.1. Innovators
6.3. Vendor Landscape
6.3.1. List of key distributors and channel partners
6.3.2. Key customers
6.3.3. Key company market share analysis, 2024
6.3.4. STERIS
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
6.3.5. SteriTek, Inc.
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Product benchmarking
6.3.5.4. Strategic initiatives
6.3.6. Sterigenics U.S., LLC
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Product benchmarking
6.3.6.4. Strategic initiatives
6.3.7. IBA Industrial Solutions
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Product benchmarking
6.3.7.4. Strategic initiatives
6.3.8. E-BEAM Services, Inc
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Product benchmarking
6.3.8.4. Strategic initiatives
6.3.9. KUB Technologies Inc.
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Product benchmarking
6.3.9.4. Strategic initiatives
6.3.10. Precision X-Ray
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Product benchmarking
6.3.10.4. Strategic initiatives
6.3.11. Hopewell Designs, Inc
6.3.11.1. Company overview
6.3.11.2. Financial performance
6.3.11.3. Product benchmarking
6.3.11.4. Strategic initiatives
6.3.12. Raycision Medical Technology Co.
6.3.12.1. Company overview
6.3.12.2. Financial performance
6.3.12.3. Product benchmarking
6.3.12.4. Strategic initiatives
6.3.13. PTW Freiburg GmbH
6.3.13.1. Company overview
6.3.13.2. Financial performance
6.3.13.3. Product benchmarking
6.3.13.4. Strategic initiatives